Consensus estimates for Cerenome, Inc. project a Q2 2026 loss of $0.96 per share on revenue of $1.11 million, with the micro-cap stock trading at $3.84 against a $36.00 average analyst price target.
Investors are primarily focused on the commercial ramp-up of the CNSide® diagnostic platform and the successful transition to a new revenue cycle management system to capture a backlog of unbilled tests.
This earnings report is the company’s first following its strategic rebranding from Plus Therapeutics, signaling a shift toward integrated CNS oncology that combines therapeutics, diagnostics, and AI data. Market participants are also monitoring clinical milestones for its lead radiotherapeutic, REYOBIQ™, including enrollment updates for Phase II trials in glioblastoma and leptomeningeal metastases.